| Dr Cynthia E Villalobos Ortiz, OD | |
|
#61 Avenida Garrido Morales, Fajardo, PR 00738 | |
| (787) 860-4090 | |
| (787) 863-5515 |
| Full Name | Dr Cynthia E Villalobos Ortiz |
|---|---|
| Gender | Female |
| Speciality | Optometrist |
| Location | #61 Avenida Garrido Morales, Fajardo, Puerto Rico |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710956339 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 310 (Puerto Rico) | Primary |
| Provider Name | Optical Factory Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1447673397 PECOS PAC ID: 6002167392 Enrollment ID: O20180926000660 |
News Archive
Gene therapy shows promise as a way to treat and cure presently incurable neurological diseases, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).
The only long term solution to severe or morbid obesity, as found by the National Institutes of Health, is surgery. When someone has tried diet and other means to lose weight and has failed, surgery is the only option.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The Children's Hospital has begun the construction of a 10-story, 350,000-square-foot addition. The $230 million expansion of a new patient tower initially will have 124 beds, with two floors of shelled space for additional future beds, bringing the total number of patient beds at Children's to around 500 upon full completion. The expansion also is expected to bring approximately 500 new jobs to the hospital's workforce. Children's anticipates admitting patients in the LEED-certified tower beginning in late 2012.
A study of the pathophysiology of this rare disease has uncovered one mechanism that destabilizes the homeostatic balance of brain cells causing edema.
› Verified 7 days ago
| Provider Name | My Optical Factory Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1518580943 PECOS PAC ID: 5890185920 Enrollment ID: O20211206000412 |
News Archive
Gene therapy shows promise as a way to treat and cure presently incurable neurological diseases, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).
The only long term solution to severe or morbid obesity, as found by the National Institutes of Health, is surgery. When someone has tried diet and other means to lose weight and has failed, surgery is the only option.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The Children's Hospital has begun the construction of a 10-story, 350,000-square-foot addition. The $230 million expansion of a new patient tower initially will have 124 beds, with two floors of shelled space for additional future beds, bringing the total number of patient beds at Children's to around 500 upon full completion. The expansion also is expected to bring approximately 500 new jobs to the hospital's workforce. Children's anticipates admitting patients in the LEED-certified tower beginning in late 2012.
A study of the pathophysiology of this rare disease has uncovered one mechanism that destabilizes the homeostatic balance of brain cells causing edema.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Cynthia E Villalobos Ortiz, OD Po Box 1400, Fajardo, PR 00738-1400 Ph: (787) 860-4090 | Dr Cynthia E Villalobos Ortiz, OD #61 Avenida Garrido Morales, Fajardo, PR 00738 Ph: (787) 860-4090 |
News Archive
Gene therapy shows promise as a way to treat and cure presently incurable neurological diseases, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).
The only long term solution to severe or morbid obesity, as found by the National Institutes of Health, is surgery. When someone has tried diet and other means to lose weight and has failed, surgery is the only option.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The Children's Hospital has begun the construction of a 10-story, 350,000-square-foot addition. The $230 million expansion of a new patient tower initially will have 124 beds, with two floors of shelled space for additional future beds, bringing the total number of patient beds at Children's to around 500 upon full completion. The expansion also is expected to bring approximately 500 new jobs to the hospital's workforce. Children's anticipates admitting patients in the LEED-certified tower beginning in late 2012.
A study of the pathophysiology of this rare disease has uncovered one mechanism that destabilizes the homeostatic balance of brain cells causing edema.
› Verified 7 days ago
New Eyes Optical Center Optometrist Medicare: Not Enrolled in Medicare Practice Location: 194 Int. Carr. 940 Km 147, Plaza Fajardo, Fajardo, PR 00738 Phone: 787-863-6110 Fax: 787-863-2878 | |
Eye Center Boutique Optometrist Medicare: Not Enrolled in Medicare Practice Location: Plaza Fajardo, Carr 3 Km 43.3 Suite 125, Fajardo, PR 00738 Phone: 787-801-5896 | |
Pearle Vision Optometrist Medicare: Not Enrolled in Medicare Practice Location: 15 Calle Garrido Morales W, Fajardo, PR 00738 Phone: 787-863-3580 Fax: 787-860-1333 | |
Dr. Joel A. Torrens, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 155, Munoz Rivera Norte, Fajardo, PR 00738 Phone: 787-863-8888 | |
Jose J Loyola, Martinez, Optometrist Medicare: Medicare Enrolled Practice Location: Munoz Rivera Esq Garrido Morales #1, Fajardo, PR 00738 Phone: 787-860-1767 Fax: 787-860-1767 | |
My Optical Factory Llc Optometrist Medicare: Medicare Enrolled Practice Location: #61 Calle Garrido Morales W, Fajardo, PR 00738 Phone: 787-860-4090 Fax: 787-863-5515 | |
Ohi Of Puerto Rico, Llc Optometrist Medicare: Not Enrolled in Medicare Practice Location: Pr 3 Int 940 Plaza Fajardo, Edificio 1212 A, Fajardo, PR 00738 Phone: 787-863-3580 |